Impact of intraoperative dexmedetomidine on clear cell renal cell carcinoma progression: a retrospective cohort study
Authors' conclusion
Intraoperative administration of dexmedetomidine was not associated with a significant impact on cancer progression and survival.
Study context
- Population
- Patients with clear cell renal cell carcinoma (RCC) undergoing partial or total nephrectomy
- Participants
- 1,766 patients
- Exposure
- Intraoperative dexmedetomidine vs no dexmedetomidine
- Outcome
- Recurrence-free survival and overall survival
Methodological detailspropensity score matching, multivariable analysis, in silico analysis of a public database
- Propensity score matching
- Multivariable analysis
- In silico analysis of a public database
Main finding
As reported in the abstract
- Dexmedetomidine not associated with higher rates of recurrence or mortality or with a significant impact on recurrence-free or overall survival
Observational data: associations, not effects.
Further findings
Tumour ADRA2A gene expression (in silico analysis)
- Not associated with recurrence-free survival; higher expression significantly associated with shorter overall survival
Original publication
Impact of intraoperative dexmedetomidine on clear cell renal cell carcinoma progression: a retrospective cohort study. Br J Anaesth. Published 9 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →